ACP3 and prostate carcinoma: Currently, two immunotherapies are approved for the treatment of prostate cancer: sipuleucel-T, an autologous cellular immunotherapy targeting prostatic acid phosphatase (PAP) for the treatment of asymptomatic or minimally symptomatic mCRPC and pembrolizumab, an immune checkpoint inhibitor (ICI) for treatment of microsatellite instability-high or mismatch repair-deficient prostate cancer in patients who have exhausted available therapies [14, 15].